

SHORT CV - CLAUDIO BRANCOLINI

Address Dep. of Medicine Università di Udine p.le Kolbe 4

33100 Udine ITALY claudio.brancolini@uniud.it

<https://people.uniud.it/page/claudio.brancolini>

ORCID iD: <https://orcid.org/0000-0002-6597-5373>

○ RESEARCH OUTPUTS

Bibliometrics

Claudio Brancolini is the first or corresponding author in 73% of the 96 PubMed indexed scientific publications. The H-index is 46 (Google Scholar) or 38 (Scopus). Total citations of his manuscripts are >18.700 (Google Scholar) or >11.600 (Scopus).

Publications

97 Scientific publications on peer-reviewed international journals in PubMed

J. Biol. Chem. (9); Mol. Biol. Cell. (5); Cell Death Diff, (5), J Cell Biol., (4); J. Cell Sci.,(3); Dev. Biol. (2); Mol Cell. Biol. (5); Drug Resist Updates (2); Autophagy (3); Adv.C. Phat. (2), Cancer Res. (2); Cell Death Disease (2), Mol. Cancer Ther. (2), Cancers (2), Nucleic Acid Res (2), Epigenomics (2), EMBO J., (2); Mol Oncol. (2), Genes Dev, (1); Exp. Cell. Res. (1); Genomics, (1); J. Neurosc. (1); J. Neurochem. (1); Gene (1); Neurobiol. Dis. (1); Oncogene (1); Leukemia (1); Curr Mol Pharm (1); AJTR (1), Apoptosis (1), Cytokine Growth Factor Review (1) Cell. Signal (1), Meth Mol Biol (1). JCOMM (1) FASEBJ (1) Proc. Natl. Acad. Sci. USA, (1) Cancer Biol & Therapy (1) PlosOne (1) Cell Mol. Life Sci. (1) J Med Chem (1) Oncotarget (1), Cell Cycle (1) CurrMedChem (1) Cells (1), Cancer Gene Ther (1), Life (1), Int J Mol Sci. (1) PLOSGenetics (1), J Cachexia Sarcopenia Muscle (1), Pharma. Therap. (1), Front Immunol.(1), Genome biology (1), Mol. Biomedicine (1), Biochim Biophys Acta Rev Cancer (1). Cell Death Discovery (1), Pharma. Therap. (1), RSC Adv. (1), Front Mol Biosci (1), IRCMB (1).

71 Scientific publications on peer-reviewed journals as first or corresponding author in PubMed

J. Biol., Chem. (6), Mol. Biol. Cell. (5), J Cell Biol. (3), Mol. Cell. Biol (3); J. Cell Sci. (3), Cell Death Diff. (2), Epigenomics (2), Drug Resist Update (2), Cell Death & Disease (2), Ad.C.Phat. (2) Cancer Res. (2) Mol. Cancer Ther (2), Epigenomics (2), Cancers (2), Nucleic Acid Res (2), Curr Mol Pharm (1). Autophagy (1) AJTR (1) Dev. Biol. (1) Proc. Natl. Acad. Sci. USA, (1); EMBO J. (1), JCOMM (1), FASEBJ (1), Meth Mol Biol (1), Apoptosis (1), CGFR (1) Cell. Signal (1) Cancer Biol & Therapy (1) PlosOne (1) Cell Mol. Life Sci. (1) J Med Chem (1)) Oncotarget (1), Cell Cycle (1) PLoS Genetics (1), Cytokine Growth Factor Review (1), Cells (1), Cancer Gene Ther (1), Life (1), Int J Mol Sci. (1), Cells (1), Genome biology (1), Mol. Biomedicine (1), Biochim Biophys Acta Rev Cancer (1), Pharma. Therap. (1). Cell Death Discovery (1), Front Mol Biosci (1), IRCMB (1).

Research Grants on competitive bases

Research activities in his Lab have been supported by different agencies including:

- Italian Ministry of University and Research PRIN, different years since 2000, currently (2019-22)
- Italian Ministry of University and Research FIRB 2003 and 2010.
- Italian Association for Cancer Research (AIRC), various years 2001-2017 Currently (2022-2026)
- Telethon, 2001-2003
- National Research Council, 1999-2001
- Italian Ministry for Health, (2002 and 2005)
- Regione Friuli-Venezia Giulia, (2005, 2009, 2017)
- Consorzio Interuniversitario per le Biotecnologie (2004)
- EU-cofounded Interreg projects ITA-SLO 2016-2018 and currently ITA-AUS, (as coordinator of the project) 2019-2022

- POR-FESR Regione FVG, 2017-2019
- Sarcoma Foundation of America (USA) 2019-2020

Awards/Fellowships

1992 Award as most promising young scientist of the Friuli Venezia Giulia.

1989-1991 Area Fellowship

1991-1993 AIRC Fellowship (Associazione Italiana per la Ricerca sul Cancro)

1999 FIRC Fellowship for working abroad (Fondazione Italiana per la Ricerca sul Cancro)

- TRAINING AND RESEARCH ACTIVITIES

Education

- 1988 Degree in Biology Università of Trieste with 110/110 and laude
- 1989 Attended EMBO course "Antibodies in Cell Biology" European Molecular Biology Laboratory Heidelberg Germany.
- 1991 Attended FEBS course "Techniques in Cell Biology" Aarhus University Denmark.
- 1995 Attended EMBO course "Tissue in situ hybridization in animal developmental biology" University of New Castle Medical School (UK).

Visiting scientist

- 1997 Chinese University of Hong-Kong (China)
- 1999 Cold Spring Harbor Laboratory New York (USA)

Research activities

- 1986-1988: Undergraduate student - Department of Biology, University of Trieste. Field of study: Immunology.
- 1988 – 1991 Post-graduate fellow at the ICGEB-UNIDO International Centre for Genetic Engineering and Biotechnology Trieste (ITALY). Field of study: Cellular and Molecular Biology. Characterization of proteins down-regulated during cellular transformation.
- 1991-1994 Post-doctoral fellow at the L.N.C.I.B. Laboratorio Nazionale Consorzio Interuniversitario per le Biotecnologie AREA Science Park Trieste (ITALY). Field of study: Cellular and Molecular Biology. Working on the molecular and cellular aspect of the G₀ phase of the cell cycle. Characterization of the genes expressed during growth arrest.
- 1995- 1998. Assistant professor at the University of Udine Medical School. Field of study: Cellular and Molecular Biology, Molecular Genetics. Working on the cellular and molecular aspect of apoptosis. Identification of caspase substrates and studies on their relevance in the apoptotic program. Molecular genetics of the peripheral neuropathies.
- 1999. Visiting scientist – Cold Spring Harbor Laboratory NY USA. Field of study: Cellular and Molecular Biology of the cell death.
- 2001-2012: Associate Professor of Biology at the Department of Biomedical Science, Medical School University of Udine (ITALY). Group leader. Field of study: Cell and Molecular Biology, Molecular Pharmacology, Molecular genetics, In vivo imaging. Characterization of genes and drugs triggering cell death, in order to develop new anti-tumor therapies.
- 2013-up to now Full Professor of Biology at the Department of Medicine University of Udine (ITALY). Field of study: Cell and Molecular Biology, Cancer Biology. Studies on the MEF2-class IIa HDACs regulative axis.

- TEACHING ACTIVITIES

- Since 1992, Claudio Brancolini has taught biology in various undergraduate courses with three-year bachelor's degrees in health:

- obstetrics,
 - nursing,
 - radiology technicians
 - laboratory technicians
 - physiotherapists
 - sports science
 - biotechnology.
 - He also teaches or has taught in master's degree programmes in biotechnology and sports science.
 - He also teaches at the MD course in Medicine and Surgery.
- ACADEMIC ROLES
 - 2003-2009 Vice-director of the Department of Biomedical Sciences at the University of Udine
 - 2011-2013 Vice-director of the Department of Medicine and Biology at the University of Udine
 - 2018- up to now, supervisor of the bioinformatics facility at the department of medicine (UniUd).
 - 2018- up to now, supervisor of the cell imaging facility at the department of medicine (UniUd).
 - 2010-2021 Coordinator of the PhD program in Biomedical Sciences and Biotechnology
 - 2021-up to now Board of Teachers at the Scuola Superiore Università degli Studi di Udine
 - EVALUATION EXPERIENCES

Academic

- 2003-2009 He serves on the Research Evaluation Panel for the University of Udine.
- 2013-2015 He serves on the Research Evaluation Panel for the University of Trieste.
- 2022-up to now, member of the *Presidio di qualità* of the University of Udine.
- 2021-2023 Member of the National committee for the Abilitazione Scientifica Nazionale to access at full and associate professor positions in Cell Biology (il settore concorsuale 05/F1 Biologia applicata) Ministero Università e Ricerca Italy.
- 2008-2013 Member of the Evaluation Committee for spin-off and start-up at the University of Udine
- 2013-2015 Member of the Evaluation Committee for patenting at the University of Udine
- Since 2022 Expert in the biological and biomedical field for the Technical Evaluation Committee, Regione Friuli-Venezia Giulia

Editorial - Reviewer

He has served as reviewer of several scientific journals among which:

FEBS letter, Cell Death and Differentiation, Nature Cell Biology, Oncogene, Journal of Biological Chemistry, British Journal of Pharmacology, European Journal of Applied Physiology. International Journal of Cancer, Cell Research, Molecular and Cellular Biochemistry, Vascular Pharmacology, Cancer Research, Leukemia, Molecular and Cellular Biology, Molecular Cancer Therapeutic, J. Molecular Biology, Journal of Clinical Pathology, BMC cancer, Cancer letters, FASEB J, Haematologica, Journal of Cellular and Molecular Medicine, Current molecular medicine, PlosONE, Carcinogenesis, Exp. Cell Res., Apoptosis, BMC-Biotec. Cell Biochemistry & Function, Cell Biology and Toxicology, Molecular Cancer, Epigenomics, Autophagy, Zeitschrift für Naturforschung, International Journal of Cell Biology, Mol Biol Cell, FEBSJ, BMC Cancer, Journal of Cell Science, Scientific Reports, Oncotarget, Journal of Translational Medicine, BBA Mol. Cell Res, Cell Death & Disease, Life, IJBS, Front. Oncology, Cellular & Molecular Biology Letters, Computational and Structural Biotechnology Journal, Cancer comm., Cancer Gene Th., Cell Genomics, Drug Res Up, J Clin Inv.

Research Grants, research grant

Italian Association for Cancer Research, Swiss National Science Foundation, ICGEB (International Centre for Genetic Engineering and Biotechnology). University of Padova, Research, Grant Council Hong-Kong, MIUR (Italian Ministry of Education, University and Research), Swiss Federation Against Cancer. Czech Science Foundation (GACR), Agence Nationale de la Recherche (France), Israel Science Foundation (Israel). Wellcome-trust (UK), Romanian National Council for Scientific Research, The Brain Tumor Charity, Neurological Foundation of New Zealand, Croatian Science Foundation, Institut National du Cancer (France), Irish Research Council (Ireland), National Science Center (Poland), World Wide Cancer Research (UK).

Editorial Board - Memberships

Drug Resistance Updates. Elsevier, AJTR - American Journal of Translation Medicine, AJCR - American Journal of Cancer Research, Life (Basel), BMC Molecular and Cellular Biology, Experimental and Therapeutic Medicine.

- TECHNOLOGY TRANSFER

- He has co-patented the DNA encoding a stimulating factor for the axl receptor (US Patent 5,538,861), ultimately acquired by AMGEN.
- He has identified novel inhibitors of de-ubiquitinases, which are currently marketed by Merck-Millipore and SantaCruz Biotec.
- Marketed by Millipore an antibody that he developed against the protein USP33.

The undersigned, aware of the penalties provided for by the penal code, and by special laws against anyone who issues false declarations, also aware of the possibility of losing the benefits resulting from any provisions issued on the basis of untruthful declaration, declares that everything stated in the curriculum vitae corresponds to truth - art. 46, D.P.R. 445/2000.

Udine 15.05.2023

Prof. Claudio Brancolini
BRNCLD62P25L424I

